CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 7, Issue 6, Pages e567
Publisher
Springer Nature
Online
2017-06-02
DOI
10.1038/bcj.2017.52
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation
- (2016) Brian C. Shaffer et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial
- (2016) Dean A. Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice
- (2015) E. M. Lee et al. HAEMATOLOGICA
- Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice
- (2015) E. M. Lee et al. HAEMATOLOGICA
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
- (2014) S. Gill et al. BLOOD
- Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia
- (2014) K. Stringaris et al. HAEMATOLOGICA
- Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC
- (2014) S J Busfield et al. LEUKEMIA
- Natural killer cells in the treatment of high-risk acute leukaemia
- (2014) Franco Locatelli et al. SEMINARS IN IMMUNOLOGY
- Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
- (2014) A Ehninger et al. Blood Cancer Journal
- Monoclonal antibody targeting of IL-3 receptor with CSL362 effectively depletes CML progenitor and stem cells
- (2013) E. Nievergall et al. BLOOD
- Antibody therapy for acute myeloid leukaemia
- (2013) Robin E. Gasiorowski et al. BRITISH JOURNAL OF HAEMATOLOGY
- Is it time to revisit standard post-remission therapy?
- (2012) Richard M. Stone BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- The myth of the second remission of acute leukemia in the adult
- (2012) S. J. Forman et al. BLOOD
- Current treatment of acute myeloid leukemia
- (2012) Gail J. Roboz CURRENT OPINION IN ONCOLOGY
- Natural killer cell immune escape in acute myeloid leukemia
- (2012) E Lion et al. LEUKEMIA
- Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells
- (2012) S.-R. Kuo et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Concise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia
- (2012) Betty K. Hamilton et al. STEM CELLS
- Natural killer cell activity influences outcome after T cell depleted stem cell transplantation from matched unrelated and haploidentical donors
- (2011) Peter Lang et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
- (2011) A. Curti et al. BLOOD
- Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations
- (2011) Roberta Riccioni et al. BRITISH JOURNAL OF HAEMATOLOGY
- Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands
- (2011) Beatriz Sanchez-Correa et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes
- (2011) Gerald B Wertheim et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study
- (2011) F. Vergez et al. HAEMATOLOGICA
- Therapeutic Advances in Acute Myeloid Leukemia
- (2011) Alan Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission
- (2010) Nicolas Dauguet et al. AMERICAN JOURNAL OF HEMATOLOGY
- Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
- (2010) P. Valent CURRENT CANCER DRUG TARGETS
- Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia
- (2010) Evgeny Klyuchnikov et al. LEUKEMIA & LYMPHOMA
- Targeting Myeloid Leukemia Stem Cells
- (2010) C. T. Jordan Science Translational Medicine
- Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients
- (2009) G Pittari et al. BONE MARROW TRANSPLANTATION
- Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells
- (2009) Liqing Jin et al. Cell Stem Cell
- Stem cell concepts renew cancer research
- (2008) J. E. Dick BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now